Pancreatic Cancer Research

ResearcherMichael E. DeBakey VA Medical CenterActive in the last 2 years

Ernest Ramsay Camp

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0003-0005-7536; OpenAlex author ID A5022537592; NIH RePORTER profile ID 9563492. Sources: OpenAlex.

Their work

Papers
13 (first author 1, last author 9)
Trials
0
Grants
1
Labs led
2
Collaborators
28
Papers, trials and grants by year

2012: 1 paper · 2013: 1 paper · 2014: 1 paper, 1 grant · 2015: none · 2016: 1 paper · 2017: none · 2018: none · 2019: 1 paper · 2020: none · 2021: 1 paper · 2022: 1 paper · 2023: 1 paper · 2024: 2 papers · 2025: 2 papers · 2026: 1 paper

Papers 13

  1. Missed Opportunities for Multimodality Therapy in Resectable Pancreatic Cancer: National Disparities and Consequences for Survival. Last author DOI 10.1002/jso.70408↗
  2. Tumor Immune Microenvironment Differences Associated With Racial Disparities in Pancreatic Cancer. Last author DOI 10.1016/j.jss.2025.01.005↗
  3. Mechanistic and functional characterization of ABTB2 as a novel target for pancreatic cancer therapy. Co-author DOI 10.1016/j.omton.2025.201080↗
  4. Sphingosine-1-Phosphate Inhibition Increases Endoplasmic Reticulum Stress to Enhance Oxaliplatin Sensitivity in Pancreatic Cancer. Last author DOI 10.14740/wjon1768↗
  5. Translational and oncologic significance of tertiary lymphoid structures in pancreatic adenocarcinoma. Last author DOI 10.3389/fimmu.2024.1324093↗
  6. Pre-treatment inflamed tumor immune microenvironment is associated with FOLFIRINOX response in pancreatic cancer. Last author DOI 10.3389/fonc.2023.1274783↗
  7. Factors associated with inability to return to intended oncologic treatment in pancreatic cancer. Last author DOI 10.1016/j.amjsurg.2022.02.058↗
  8. High-Fat Diet Drives an Aggressive Pancreatic Cancer Phenotype. Last author DOI 10.1016/j.jss.2020.10.007↗
  9. Genomics meets immunity in pancreatic cancer: Current research and future directions for pancreatic adenocarcinoma immunotherapy. Last author DOI 10.4081/oncol.2019.430↗
  10. The CaSm (LSm1) oncogene promotes transformation, chemoresistance and metastasis of pancreatic cancer cells. First author DOI 10.1038/oncsis.2015.45↗
  11. Phase 2 trial of induction gemcitabine, oxaliplatin, and cetuximab followed by selective capecitabine-based chemoradiation in patients with borderline resectab… Co-author DOI 10.1016/j.ijrobp.2013.12.030↗
  12. Transferrin receptor targeting nanomedicine delivering wild-type p53 gene sensitizes pancreatic cancer to gemcitabine therapy. Co-author DOI 10.1038/cgt.2013.9↗
  13. Novel immunocompetent murine models representing advanced local and metastatic pancreatic cancer. Last author DOI 10.1016/j.jss.2011.10.025↗

Grants 1

  1. Innovative Delivery Strategy for CaSm Gene Therapy in Pancreatic Cancer K08CA142904↗

Closest collaborators

The 25 strongest of 28 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. George Van Buren · 4 shared papers, 2022–2026 · strength 0.91
  2. Zachary Gao · 4 shared papers, 2023–2025 · strength 0.83
  3. Derek J. Erstad · 3 shared papers, 2023–2026 · strength 0.74
  4. Mark P. Rubinstein · 4 shared papers, 2019–2025 · strength 0.74
  5. Eric Jay Silberfein · 2 shared papers, 2022–2026 · strength 0.50
  6. John C. Johnson · 1 shared paper, 2026 · strength 0.33
  7. William E Fisher · 1 shared paper, 2026 · strength 0.33
  8. Nan Lyu · 1 shared paper, 2025 · strength 0.24
  9. Xinjian Liu · 1 shared paper, 2025 · strength 0.24
  10. Eric T. Kimchi · 1 shared paper, 2025 · strength 0.24
  11. Guangfu Li · 1 shared paper, 2025 · strength 0.24
  12. Yi Miao · 1 shared paper, 2025 · strength 0.24
  13. Olamide Tosin Olaoba · 1 shared paper, 2025 · strength 0.24
  14. Kun Cheng · 1 shared paper, 2025 · strength 0.24
  15. Shalini Makawita · 1 shared paper, 2024 · strength 0.21
  16. David J. Cole · 4 shared papers, 2012–2016 · strength 0.18
  17. William E. Fisher · 1 shared paper, 2022 · strength 0.16
  18. Onur Cagri Kutlu · 1 shared paper, 2022 · strength 0.16
  19. Townes A Mickel · 1 shared paper, 2022 · strength 0.16
  20. Denise I. Garcia · 1 shared paper, 2021 · strength 0.16
  21. Elizabeth C. Little · 3 shared papers, 2012–2016 · strength 0.14
  22. Dennis K. Watson · 3 shared papers, 2012–2016 · strength 0.14
  23. Chrystal M Paulos · 1 shared paper, 2019 · strength 0.12
  24. Jacob S. Bowers · 1 shared paper, 2019 · strength 0.12
  25. Nestor F. Esnaola · 1 shared paper, 2014 · strength 0.04

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.